Seagen Inc. SGEN
Set alert
At close · Dec 13
52-week range unavailable
- Open
- 228.93
- Prev close
- 228.74
- Mkt cap
- 43.15B
- Vol
- 19.39M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 228.74
- High
- 228.96
- Forward P/E
- -156.67
- Beta
- 0.32
- Short ratio
- 8.69
- Inst. own
- 88.83%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 1, 2023
- 50-d avg
- 217.43
- 200-d avg
- 204.65
- 1y target
- 229.00
5Y chart
Events in this range
- Jul 28, 2022Earnings: —; estimate -0.82; surprise —%
- Oct 27, 2022Earnings: —; estimate -0.92; surprise —%
- Feb 15, 2023Earnings: —; estimate -1.02; surprise —%
- Mar 19, 2023Rating: Truist Securities · — → Hold
- Mar 20, 2023Rating: TD Securities · — → Market Perform
- Mar 23, 2023Downgrade: Berenberg · Buy → Hold
- Apr 27, 2023Earnings: —; estimate -0.82; surprise —%
- Aug 2, 2023Earnings: —; estimate -0.78; surprise —%
- Aug 2, 2023Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Sep 24, 2023Rating: Truist Securities · Hold → Hold
- Oct 17, 2023Rating: Truist Securities · Hold → Hold
- Nov 1, 2023Earnings: —; estimate -0.71; surprise —%
Signals (30)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Dec 14, 2023 | 2 years ago |
| RSI: Overbought | Dec 14, 2023 | 2 years ago |
| SMA: Bullish | Dec 7, 2023 | 2 years ago |
| SMA: Bearish | Nov 15, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 8, 2023 | 2 years ago |
| RSI: Overbought | Oct 10, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 26, 2023 | 3 years ago |
| RSI: Overbought | Sep 26, 2023 | 3 years ago |
| SMA: Bullish | Aug 29, 2023 | 3 years ago |
| SMA: Bearish | Jul 25, 2023 | 3 years ago |
| SMA: Bullish | Jul 18, 2023 | 3 years ago |
| SMA: Bearish | Jun 27, 2023 | 3 years ago |
| SMA: Bullish | Jun 20, 2023 | 3 years ago |
| MACD: Sell Signal | May 30, 2023 | 3 years ago |
| SMA: Bearish | May 16, 2023 | 3 years ago |
| RSI: Overbought | Mar 14, 2023 | 3 years ago |
| RSI: Overbought | Feb 28, 2023 | 3 years ago |
| SMA: Bullish | Feb 14, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 10, 2023 | 3 years ago |
| SMA: Bullish | Jan 3, 2023 | 3 years ago |
Newest 20 of 30.
Key statistics
- Market cap
- 43.15B
- Enterprise value
- 42.04B
- Trailing P/E
- 0.00
- Forward P/E
- -156.67
- PEG ratio
- 0.55
- Price / sales
- 18.76
- Price / book
- 16.92
- EPS (TTM)
- -4.00
- Beta
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -32.61%
- Revenue (TTM)
- 2.30B
- Revenue growth
- 27.10%
- Free cash flow
- -277.09M
- Total cash
- 1.24B
- Total debt
- 124.58M
- Return on equity
- -27.93%
- Shares outstanding
- 188.66M
- Short % of float
- 6.79%
- 50-day average
- 217.43
- 200-day average
- 204.65
Analyst view
Consensus: buy
- Strong buy3
- Buy5
- Hold8
- Sell0
- Strong sell0
Next earnings
Nov 1, 2023
Expected Nov 1, 2023. Consensus EPS estimate -1.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2023 | Sep 1, 2023 | -0.71 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.78 | — | — | — |
| Apr 27, 2023 | Mar 1, 2023 | -0.82 | — | — | — |
| Feb 15, 2023 | Dec 1, 2022 | -1.02 | — | — | — |
| Oct 27, 2022 | Sep 1, 2022 | -0.92 | — | — | — |
| Jul 28, 2022 | Jun 1, 2022 | -0.82 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2023 | Truist Securities | reit | Hold | Hold |
| Sep 24, 2023 | Truist Securities | reit | Hold | Hold |
| Aug 2, 2023 | Morgan Stanley | reit | Equal-Weight | Equal-Weight |
| Mar 23, 2023 | Berenberg | down | Buy | Hold |
| Mar 20, 2023 | TD Securities | main | — | Market Perform |
| Mar 19, 2023 | Truist Securities | main | — | Hold |
About Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seagen.com
News
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- Earnings Scheduled For November 1, 2023
- Earnings Scheduled For August 2, 2023
- Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
- From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
- Earnings Scheduled For April 27, 2023
- Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
- Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
- Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Illumina, Seagen And Other Big Stocks Moving Higher On Monday
Your note
Sign in to keep a note on SGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 30, 2023 | 0 |
| DANSEY ROGER D | Officer | Sale | Sep 20, 2023 | 116,677 |
| EPSTEIN DAVID R | Chief Executive Officer | Sale | Nov 9, 2023 | 136,598 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | May 30, 2023 | 51,047 |
| HIMES VAUGHN B | Chief Technology Officer | Sale | Nov 8, 2023 | 162,045 |
| LIU JEAN I | Officer | Sale | Sep 20, 2023 | 84,398 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 23.74% | 44,554,162 | 8.57B | Jun 29, 2023 |
| Vanguard Group Inc | 7.09% | 13,315,658 | 2.56B | Jun 29, 2023 |
| Blackrock Inc. | 6.42% | 12,041,819 | 2.32B | Jun 29, 2023 |
| Pentwater Capital Management Lp | 5.13% | 9,629,500 | 1.85B | Jun 29, 2023 |
| Capital World Investors | 4.84% | 9,081,409 | 1.75B | Jun 29, 2023 |
| Capital International Investors | 3.42% | 6,417,224 | 1.24B | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 3.52% | 6,610,163 | 1.27B | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.34% | 4,396,581 | 846.17M | Jun 29, 2023 |
| Vanguard Mid-Cap Index Fund | 1.74% | 3,259,531 | 627.33M | Jun 29, 2023 |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.69% | 3,177,667 | 654.82M | Aug 30, 2023 |
| Vanguard Horizon Fund-Capital Opportunity Fund | 1.21% | 2,274,960 | 437.84M | Jun 29, 2023 |
| New Perspective Fund Inc | 1.20% | 2,260,964 | 435.15M | Jun 29, 2023 |